Fail Safe Cell Therapy

1-888-613-6862
info@pancella.com

Mesenchymal stromal cells improve cardiac function and left ventricular remodeling in a heart transplantation model.

Sonia Montanari, Victor Dayan, Gustavo Yannarelli, Filio Billia, Sowmya Viswanathan, Kim A Connelly, Armand Keating
J Heart Lung Transplant 2015 Nov 12;34(11):1481-8. Epub 2015 Jun 12.

Ischemia/reperfusion (I/R) injury is an inevitable consequence of organ transplantation and a major determinant of patient and graft survival in heart transplantation. Bone marrow-mesenchymal stromal cell (BM-MSC) treatment is a potentially effective cell therapy for cardiac disease. We investigated the effects of intravenous delivery of BM-MSCs in the acute phase post-transplant in a heterotopic heart transplantation (HHT) model associated with I/R injury…

–Source: https://www.ncbi.nlm.nih.gov/pubmed/26234284

Sorry, comments are closed for this post.